Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

5HI7

Co-crystal structure of human SMYD3 with an aza-SAH compound

Summary for 5HI7
Entry DOI10.2210/pdb5hi7/pdb
DescriptorHistone-lysine N-methyltransferase SMYD3, ZINC ION, MAGNESIUM ION, ... (6 entities in total)
Functional Keywordssmyd3, methyltransferase, oncology, inhibitor, transferase-inhibitor complex, transferase/inhibitor
Biological sourceHomo sapiens (Human)
Cellular locationCytoplasm : Q9H7B4
Total number of polymer chains1
Total formula weight50318.00
Authors
Elkins, P.A.,Bonnette, W.G. (deposition date: 2016-01-11, release date: 2016-03-30, Last modification date: 2024-03-06)
Primary citationVan Aller, G.S.,Graves, A.P.,Elkins, P.A.,Bonnette, W.G.,McDevitt, P.J.,Zappacosta, F.,Annan, R.S.,Dean, T.W.,Su, D.S.,Carpenter, C.L.,Mohammad, H.P.,Kruger, R.G.
Structure-Based Design of a Novel SMYD3 Inhibitor that Bridges the SAM-and MEKK2-Binding Pockets.
Structure, 24:774-781, 2016
Cited by
PubMed Abstract: SMYD3 is a lysine methyltransferase overexpressed in colorectal, breast, prostate, and hepatocellular tumors, and has been implicated as an oncogene in human malignancies. Methylation of MEKK2 by SMYD3 is important for regulation of the MEK/ERK pathway, suggesting the possibility of selectively targeting SMYD3 in RAS-driven cancers. Structural and kinetic characterization of SMYD3 was undertaken leading to a co-crystal structure of SMYD3 with a MEKK2-peptide substrate bound, and the observation that SMYD3 follows a partially processive mechanism. These insights allowed for the design of GSK2807, a potent and selective, SAM-competitive inhibitor of SMYD3 (Ki = 14 nM). A high-resolution crystal structure reveals that GSK2807 bridges the gap between the SAM-binding pocket and the substrate lysine tunnel of SMYD3. Taken together, our data demonstrate that small-molecule inhibitors of SMYD3 can be designed to prevent methylation of MEKK2 and these could have potential use as anticancer therapeutics.
PubMed: 27066749
DOI: 10.1016/j.str.2016.03.010
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.15 Å)
Structure validation

231029

数据于2025-02-05公开中

PDB statisticsPDBj update infoContact PDBjnumon